dihexa peptide overview 10MG VIAL – UMBRELLA Labs Dihexa UK: Evidence-Based Peptide Research

McGuire, F

Conclusion GLP-1 agonists are pivotal in managing type 2 diabetes and supporting weight loss by mimicking natural hormonal actions that regulate insulin, glucose, and appetite

Cagrilintide vs semaglutide (Wegovy/Ozempic) Mechanism: Cagrilintide: Amylin receptor agonist Semaglutide: GLP-1 receptor agonist Different pathways Weight loss: Cagrilintide alone: 10-12% Semaglutide alone: 10-15% Similar efficacy monotherapy Gastric emptying: Cagrilintide: Very strong delay Semaglutide: Moderate delay Cagrilintide more powerful Side effects: Cagrilintide: More GI effects (stronger gastric slowing) Semaglutide: Moderate GI effects Cagrilintide harder to tolerate for some Availability: Cagrilintide: Investigational (not approved) Semaglutide: FDA approved, widely available Semaglutide easier to obtain currently Combination potential: Synergistic together (CagriSema) 15-25% weight loss combined Best of both mechanisms Verdict: Similar monotherapy efficacy, but combine for maximum results

3) Suppresses postprandial glucagon secretion post-meal hyperglycemia

"My digestion has been off for a long timeespecially after travel or stress

Reduction in Cognitive Decline Associated with Aging: As a nootropic, Dihexa could play a role in mitigating age-related cognitive decline, helping maintain cognitive functions in the aging population